NASDAQ:TNXP Tonix Pharmaceuticals Q1 2025 Earnings Report $13.14 -0.23 (-1.72%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Tonix Pharmaceuticals EPS ResultsActual EPS-$3.86Consensus EPS -$3.10Beat/MissMissed by -$0.76One Year Ago EPSN/ATonix Pharmaceuticals Revenue ResultsActual Revenue$2.00 millionExpected Revenue$2.60 millionBeat/MissMissed by -$600.00 thousandYoY Revenue GrowthN/ATonix Pharmaceuticals Announcement DetailsQuarterQ1 2025Date8/11/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsTonix Pharmaceuticals' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Tonix Pharmaceuticals Earnings HeadlinesTNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26September 2 at 6:19 PM | finance.yahoo.comTonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare ConferenceSeptember 2 at 8:14 AM | finance.yahoo.comPass by August 7… or wait until 2027?I’m making my next major call for what could be one of crypto’s biggest catalysts: The CLARITY Act. The bill has already cleared a major Senate hurdle. And Washington is still working toward giving digital assets the regulatory framework institutions have been waiting for. I’ve identified one under-$1 crypto I believe could be particularly well positioned if clearer rules accelerate Wall Street’s move onto blockchain rails. It’s built around institutional finance — including tokenized assets, settlement and regulated markets. And while most investors are still focused on Bitcoin and the usual big names, I believe this lesser-known crypto deserves far more attention.September 4 at 1:00 AM | Crypto 101 Media (Ad)Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare ConferenceSeptember 2 at 7:00 AM | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street ZenAugust 29, 2026 | americanbankingnews.comTonix Pharma Names CEO Seth Lederman Interim CMOAugust 18, 2026 | tipranks.comSee More Tonix Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tonix Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tonix Pharmaceuticals and other key companies, straight to your email. Email Address About Tonix PharmaceuticalsTonix Pharmaceuticals (NASDAQ:TNXP) is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents. Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD. The company is conducting late-stage clinical trials to assess safety and efficacy in people who experience chronic pain and disrupted sleep due to these conditions. In addition to its CNS portfolio, Tonix is advancing live-virus vaccine candidates against orthopoxviruses, including those that could be used for smallpox or monkeypox, and is exploring development of vaccines against other biothreat agents. Headquartered in New York, Tonix Pharmaceuticals leverages in-house research and collaborations with academic institutions and government agencies to advance its pipeline. The company was co-founded and is led by Seth H. Lederman, M.D., who serves as President and Chief Executive Officer. Under Dr. Lederman’s direction, Tonix continues to progress multiple programs through clinical development while maintaining a focus on unmet medical needs in both therapeutic and vaccine arenas.View Tonix Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake’s AI Momentum Is Forcing a Fresh Look at the StockAeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityFB Financial's Southern Expansion and Buybacks Drive Analyst OptimismRetail Earnings Just Exposed a Bigger Divide in the U.S. Consumer EconomyAccelerant’s Take-Private Deal Raises a Bigger Question for Insurance StocksDefense Stocks Are Pulling Back as Their Navy Tailwinds Get StrongerThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
